Psychedelics
UCSF researchers test LSD-based MM120 for generalized anxiety disorder
Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo
UCSF neuroscientist Jennifer Mitchell and collaborators are evaluating MM120, a pharmaceutical form of LSD, as a potential treatment for generalized anxiety disorder. A randomized clinical trial published in JAMA found that a single dose reduced anxiety symptoms versus placebo, with benefits persisting up to 12 weeks in the optimal dose group, according to the study and the drug’s sponsor.
Researchers have found that psilocybin, the hallucinogenic compound in magic mushrooms, likely evolved as a defense mechanism against insects that feed on fungi. Experiments with fruit fly larvae showed reduced survival and impaired development when exposed to the substance. This discovery sheds light on the evolutionary purpose of psychedelics in nature.
Ti AI ṣe iroyin
Researchers in Hungary have found that DMT, a natural psychoactive compound, significantly mitigates brain damage from stroke in animal models and cell cultures. The molecule restores the blood-brain barrier and curbs inflammation, potentially complementing current treatments. These discoveries, published in Science Advances, highlight DMT's therapeutic promise amid limited stroke options.